Breast cancer is often fatal during its metastatic dissemination. To unravel the role of microRNAs (miRs) during malignancy, we analyzed miR expression in 77 primary breast carcinomas and identified 16 relapse-associated miRs that correlate with survival and/or distinguish tumor subtypes in different datasets. Among them, miR-148b, down-regulated in aggressive breast tumors, was found to be a major coordinator of malignancy. In fact, it is able to oppose various steps of tumor progression when overexpressed in cell lines by influencing invasion, survival to anoikis, extravasation, lung metastasis formation, and chemotherapy response. miR-148b controls malignancy by coordinating a novel pathway involving over 130 genes and, in particular, it directly targets players of the integrin signaling, such as ITGA5, ROCK1, PIK3CA/p110␣, and NRAS, as well as CSF1, a growth factor for stroma cells. Our findings reveal the importance of the identified 16 miRs for disease outcome predictions and suggest a critical role for miR-148b in the control of breast cancer progression.
MicroRNAs (miRs) are new players involved in the establishment and progression of human tumors that appear to be critical biomarkers of cancer with strong classification power. miRs are a class of small noncoding RNAs that negatively regulate protein-coding gene expression post-transcriptionally by targeting mRNAs, mostly at the 3= untranslated region (3=-UTR) and triggering either translation repression or RNA degradation (6) . Investigations for miR levels in human tumors showed that miR expression is altered in cancer compared to normal tissues, and these changes can help to classify tumors more accurately than mRNA expression profiles according to developmental lineage and differentiation status (7) . Recent studies demonstrated that breast cancers can be classified into specific tumor pathological phenotypes (ER, PR, proliferation, stage, metastasis, ERBB2) as well as subtypes (luminal A or B, basal-like, ERBB2
ϩ and normal-like) based on miR expression profiles (8, 9) . Thus, it seems essential to combine miR and protein-coding gene expression analyses to obtain information for prognosis and cancer treatment. miRs such as let-7, miR-9, miR-10b, miR-21, miR-31, miR-34, miR-126, miR-146, miR-155, miR-200, miR-214, miR-221/222, miR-373, and 520c have been proven to control tumor dissemination. In fact, alterations of their expression in breast cancer cells profoundly affect tumor dissemination (10 -12) . In our work, we investigated the relationship between altered miR expression and breast cancer metastasis by analyzing miR levels in a cohort of patients with breast cancer, grouped based on disease relapse. In particular, we investigated the biological function and molecular mechanism of a relapse-associated small noncoding RNA, miR-148b.
MATERIALS AND METHODS

Cell culture
Human MDAMB231, 4175 TGL (13), MCF7, and T47D cells and mouse 4T1 cells were maintained in standard conditions: Dulbecco's modified Eagle's medium containing 10 mM Glutamax and 4.5 mg/ml glucose(DMEM Glutamax; Gibco; Invitrogen Life Technologies, Carlsbad, CA, USA), supplemented with 10% heat-inactivated FCS (Biochrom AG, Berlin, Germany), 1 mM sodium pyruvate, 25 mM HEPES (pH 7.4), and 100 mg/ml gentamicin (all from Gibco).
Patients and samples
Frozen primary invasive ductal breast cancer specimens (77) from 25-to 82-yr-old patients were selected from the Tumor Bank of the Department of Obstetrics and Gynecology, University of Torino (Turin, Italy; primary surgery: 1988 -2001) for a retrospective study. There was no distant metastasis at diagnosis (M0). Complete clinical-pathological data were updated by follow-up for Ն72 mo (up to 100 mo). All patients were treated with radical modified mastectomy or quadrantectomy and axillary dissection plus breast irradiation. High-risk node-negative and node-positive patients received adjuvant treatments (generally 6 cycles of CMF: 600 mg/m 2 cyclophosphamide, 40 mg/m 2 metotrexate, 600 mg/m 2 5-fluorouracil), and/or 20 mg tamoxifen daily for 5 yr in ER ϩ cases. Patient stage distribution was assessed as prescribed by the Union for International Cancer Control (UICC) clinical staging guidelines, and tumor grading was performed as described previously (14) . As normal breast controls, 17 frozen mammoplastic reductions were included in the screening. Appropriate ethical approval was obtained for this study.
Reagents and antibodies miR precursors and inhibitors
Pre-miR miRNA Precursor Molecules-Negative Control 1, miRNA precursors hsa-miR-148b (PM10264) (000471), hsamiR-214 (PM12124), Anti-miR miRNA Inhibitor-Negative Control 1, and miRNA inhibitor hsa-miR-148b (AM10264) were from Ambion (Austin, TX, USA).
miR detection
TaqMan miRNA assays hsa-miR-148b (000471), hsa-miR-187 (000487), hsa-miR-365 (001020), hsa-miR-10a (000387), hsamiR-19a (000395), hsa-miR-342-3p (002260), hsa-miR-214 (002306), hsa-RNU44 (001094), and U6 snRNA (001973) were from Applied Biosystems (Foster City, CA, USA).
ECM
Collagen IV and fibronectin were from Sigma-Aldrich (St. Louis, MO, USA).
Apoptosis reagents
FITC-conjugated annexin V was provided by Boehringer Mannheim (Indianapolis, IN, USA). PE-conjugated annexin V was provided by BD Biosciences (Bedford, MA, USA). Tetramethylrhodamine methyl ester (TMRM) was provided by Molecular Probes (Invitrogen Life Technologies). Paclitaxel (Onco-Tain brand) was from Mayne Pharma (Melbourne, Australia), cisplatin was from Ebewe Italia Srl. (Rome, Italy), and doxorubicin was from Sigma-Aldrich.
RNAi
si ITGA5 (Hs_ITGA5_5 siRNA) and All Stars Negative Control siRNA were purchased from Qiagen (Stanford, CA, USA).
Primers
Cloning oligonucleotides employed in this study are listed in Table 1 . RT-PCR assays (Qiagen) employed in this study are listed in Table 2 .
Plasmid construction and lentiviral infections
Luciferase reporter vectors containing the partial 3=-UTR of the indicated miR-148b target genes were generated following PCR amplification of the 3=-UTR from human cDNA and cloned into the firefly luciferase reporter pMIR-Report vector (Ambion). When indicated, the 3=-UTRs were mutagenized at miR-148b recognition sites using the QuickChange Site-Directed Mutagenesis kit (Stratagene, Cedar Creek, TX, USA) according to the manufacturer's instructions. The miR-148b sensor was obtained by annealing, purifying, and cloning short oligonucleotides containing 3 perfect miR-148b binding sites into the SpeI and HindIII sites of the pMIR-Report vector. The human pre-miR-148b sequence (a 306-bp fragment containing the pre-miR sequence) was amplified from genomic DNA (MDAMB231) and cloned into pLemiR-tRFP (Open Biosystems, Huntsville, AL, USA) vector to obtain pLemiR148b (still containing tRFP) vector. The human pre-miR-187 sequence (a 251-bp fragment containing the pre-miR sequence) was amplified from genomic DNA (MDAMB231) and cloned into pWPT (Addgene, Cambridge, MA, USA) vector to obtain pWPT-miR-187 vector. Stable cell lines were generated by lentiviral infection. Lentiviruses were produced by calcium phosphate transfection of 293T cells with 20 g of specific vector together with 15 g packaging (pCMVdR8.74) and 6 g envelope (pMD2.G-VSVG) plasmids, according to D. Trono's laboratory protocol (École Polytechnique Fé-dérale de Lausanne, Lausanne, Switzerland; http://tronolab. epfl.ch). Supernatant was harvested 48 h post-transfection, filtered with 0.45-m filters, diluted, and used to infect 3.5 ϫ 10 5 cells in 6-well plates, in presence of 8 g/ml Polybrene (Sigma-Aldrich). ITGA5 overexepression was obtained by transfecting pEGFP-N3-ITGA5 expression vector (plasmid 15238; Addgene; ref. 16 ).
RNA isolation from tissues or cells
After surgical removal, tumor samples were macrodissected by pathologists, quickly frozen, and stored at Ϫ80°C. Total RNA was isolated with Concert cytoplasmic RNA reagent (Invitrogen Life Technologies) from 20 to 50 mg tumor tissues, according to the manufacturer's guidelines. Frozen tumors were then homogenized using a ball mill (MM200; Retsch, Düsseldorf, Germany). The suspension was centrifuged at 14,000 g for 5 min at 4°C, and then lysed with 0.1 ml of 10% SDS, followed by 0.3 ml of 5 M sodium chloride and Total RNA integrity and the percentage content of miRs in each sample were assessed by capillary electrophoresis using the Agilent Bioanalyzer 2100 with the RNA 6000 Nano and the Small RNA Nano LabChips, respectively (Agilent Technologies, Palo Alto, CA, USA). Only total RNA samples with an RNA integrity number (RIN) Ն 6 and Ͻ30% of small RNAs were used for miR microarray analysis.
miR and gene expression profilings
The miR and protein-coding expression profilings were carried out using the Human MicroRNA Microarray kit (V2, 723 miRs) and the Whole Human Genome Oligo Microarray (ϳ41,000, 60-mer oligonucleotide probes), respectively, both from Agilent Technologies. For miR analysis, total RNA (200 ng) was labeled with pCp-Cy3, according to the Agilent protocol (17) , and probes were hybridized at 55°C for 22 h. For protein-coding investigations, total RNA (800 ng) was labeled by the Agilent One-Color Microarray-Based Gene Expression protocol, according to the manufacturer's instructions. The synthesized cDNA was transcribed into cRNA and labeled with Cy3. Labeled cRNA (1.65 g) was used for hybridization at 65°C for 17 h. Slides were scanned on an Agilent microarray scanner. Raw miR and gene expression data are available in the U.S. National Center for Biotechnology Information Gene Expression Omnibus (GEO) database (GSE26666; http:/www.ncbi.nlm.nih.gov/geo/query/acc.cgi? token_jveltssyquiywvo&acc_GSE26666). Interarray normalization was performed with cyclic Lowess for miRs and with quantile for protein-coding expression profilings (18, 19) , and the average of replicates was used. To perform differential gene expression analysis, the level of each miR was calculated as log 2 of tumor sample/mammoplastic reduction median. The identification of differential expression for miRs or proteincoding genes was performed using the 2-class significance analysis of microarray (SAM) algorithm (20) . SAM uses a permutation-based multiple testing algorithm and associates a variable false discovery rate (FDR) to the significant genes. FDR refers to the percentage of error that can occur in the identification of the statistically significant differentially expressed genes in multiple comparisons; it can be manually adjusted.
Statistical analysis of miR and gene expression data
For miRs, Feature Extraction software (Agilent Technologies) was used to obtain spot quality measures in order to evaluate the quality and the reliability of the hybridization. In particular, the flag glsFound (set to 1 if the spot has an intensity value significantly different from the local background, 0 otherwise) was used to filter out unreliable probes: flag equal to 0 will be noted as not available (NA). So, in order to perform a more robust and unbiased statistical analysis, probes with a high proportion of NA values were removed from the dataset. NA (40%) was used as threshold in the filtering process, obtaining a total of 237 available human miRs. Principal component analysis (PCA), cluster analysis, and profile similarity searches were performed with Multi Experiment Viewer 4.5.1 (TMev) of the TM4 Microarray Software Suite (21) . All heath maps were obtained by TMeV software using an unsupervised 2-dimensional hierarchical clustering approach with average linkage method and Pearson correlation.
Statistical analyses of biological samples
Data are presented as means Ϯ sem or sd, and 2-tailed Student's t test was used for comparison analysis, with values of P Ͻ 0.05 considered to be statistically significant. Box and whisker plots were prepared based on Liu (22) . The bottom and top of the box are, respectively, the first (bottom) and third (top) quartile; the line in the middle corresponds to the median, and circles label outliers.
Statistics for survival analysis
Survival association analyses were performed using the SPSS 18.0 statistical software (SPSS Inc., Chicago, IL, USA) and the Bioconductor suite of software tools (http://www.bioconductor.org). The receiver operating characteristic (ROC) method (23) was used to categorize samples according to miR or mRNA expression. Kaplan-Meier survival curves were used to estimate time-to-event models in the presence of censored cases. Risk differences between the two groups were assessed using the Mantel-Haenszel log-rank test (24) . Survival analysis was carried out in both univariate and multivariate setting using Cox's proportional hazard model (25) . ITGA5 survival association was evaluated in GSE2034 (26); gene expression values were calculated as described previously (27) , and results were divided into two categories according to gene expression levels.
Analysis of human breast cancer data sets
Blenkiron et al. (8) and Enerly et al. (9) miR expression values and sample phenodata were obtained from GSE7842 and GSE19536, respectively, and from the supplemental materials of the publications.
Target prediction and pathway analysis
The TargetScan 5.1 algorithm (28) was used to predict miR targets. The Ingenuity Pathways Knowledge Base (http:// www.ingenuity.com) is currently the world's largest database of knowledge on biological networks, with annotations orga- COPZ1  QT00087024  CSF1  QT00035224  CTSA  QT00087381  CXCL5  QT00203686  DYRK2  QT01011073  GRB2  QT00065289  ITGA5  QT00080871  MMP15  QT00014063  NRAS  QT00076874  NRP1  QT00023009  PIK3CA  QT00014861  ROCK1  QT00034972  RRN18S  QT00199367 nized by experts. We exploited this database to look for enrichments in specific pathways among the relapse (or other category)-associated miR putative targets. Enrichment significance in pathways analysis is shown as the negative log 10 of the P value. The P value is calculated with the right-tailed Fisher's exact test. Ingenuity networks are scored based on the number of network eligible molecules they contain. The network score is based on the hypergeometric distribution and is calculated with the right-tailed Fisher's exact test. The score is the negative log of this P value. Additional cell transfections and infections, qRT-PCRs, apoptosis, luciferase assays, protein preparation, immunoblotting, and in vitro and in vivo biological studies were all performed as indicated in detail in Penna et al. (12) .
RESULTS
Sixteen relapse-associated miRs classify breast tumors
In a retrospective study, we analyzed miR expression in 77 primary human breast ductal tumors as well as 17 mammoplastic reductions (Table 3) , using microarrays (a 723-miR platform) and a 2-class SAM. In particular, when we compared patients with relapse (nϭ41) or without relapse (nϭ36), within Ն72 mo from surgery, 16 differentially expressed miRs were identified and expressed as fold changes or levels, relative to the median of the healthy controls, log 2 tumors/controls (Fig. 1) . Within relapsing/nonrelapsing patients, validation of microarray data was performed by qRT-PCR analysis for miR-148b, miR-365, and miR-10a using n ϭ 10/group (not shown). By using the 16 relapse-associated miRs together as a whole (as a group), we identified two groups of patients with different overall survival (OS; Pϭ0.018) and disease-free survival (DFS; Pϭ0.016), independent of the lymph node status (Cox proportional-hazards regression model; Pϭ0.015) in our study. The same was found when certain individual specific miRs were used, for instance, miR-148b, downregulated in relapsing tumors (OS, Pϭ0.027; DFS, Pϭ0.036). However, a correlation with survival was not found when our 16 relapse-associated miRs were used as a whole for two other available public datasets (8, 9) . These studies refer to ϳ100 patients each; the primary tumors were used to measure mRNA and miR expression with the goal of identifying tumor subtypes. Notably, in these datasets, our group of 16 relapse-associated miRs could identify tumor subtypes and separate more aggressive (ERBB2 ϩ or basal-like) vs. less aggressive (luminal A/B) cancers (Fig. 1C, compare solid vs. shaded symbols), based on the breast cancer classification in Sorlie et al. (4) . Moreover, our 16-miR signature could also predict survival, in our cohort, when only luminal tumors (nϭ53) were considered (DFS, Pϭ0.0097). In addition, some of the 16 miRs, such as miR10a, miR-101, miR-142-5p, miR-148b, miR-342-3p, miR-342-5p, miR-365, and miR-551b, could distinguish tumor subtypes individually (8, 9 and data not shown). In summary, we identified 16 relapse-associated miRs that could be used in the clinics to identify tumor subtypes and to predict disease outcome.
miR-148b impairs tumor growth and suppresses metastasis formation by altering extravasation and survival
A detailed bioinformatics analysis was carried out for the putative targets of the 16 relapse-associated miRs, as predicted by TargetScan 5.1, using Ingenuity Pathway Analysis (IPA) in order to identify pathways and functions in which each miR was involved. This analysis, together with literature searches, let us to conclude that miR-148b has the potential to coordinate a very high number of pathways relevant for breast cancer and that its function has still to be elucidated. With this in mind, we investigated the biological role of miR-148b in neoplasia by modulating (up or down) its expression in MDAMB231, 4175TGL, 4T1, T47D, and MCF7 mammary tumor cell lines with a different level of malignancy (independently of ER, PR, and ERBB2 expression) and of miR-148b, as measured by qRT-PCR (Supplemental Fig. S1A ). Transient modulations were obtained using miR-148b precursors or inhibitors or negative controls (pre-miR-148b, anti-miR-148b, or precontrol or anticontrol) and evaluated 48 or 72 h post-transfection for expression and biology (Supplemental Fig. S1B, C) . Instead, for stable expression, cells were transduced with pLemiR-empty or pLemiR-148b overexpressing lentivirus vectors and selected with puromycin as pools; expression evaluation is shown in Supplemental Fig. S1C .
In vitro proliferation was not affected or only slightly modulated up to 4 d for MDAMB231, 4175TGL, and 4T1 cells in stable or transient conditions (Supplemental Fig. S2A and data not shown). However, tumors derived from transduced pLemiR-148b 4175TGL cells grew significantly less compared to controls (pLemiR-EV) when analyzed up to 12 d following injection in the fat pad of immunocompromised NOD/SCID IL2R␥ null mice (see below). When invasion through fibronectin or Matrigel was evaluated by transwell assays for the same cell lines, reduced cell movement was observed in the presence of miR-148b overexpression compared to controls (Supplemental Fig. S2B and data not shown). However, no effect was observed when cells were transduced with pWPT-miR-187 (negative control) lentivirus overexpression vectors compared to controls (pWPT-EV or precontrol; Supplemental Fig. S2B and data not shown). Instead, increased cell invasion was observed when miR-214 was overexpressed in these cells (Supplemental Fig. S2B, ref. 12 , and data not shown). When cell adhesion was investigated, increased adhesion on fibronectin and collagen IV was found for MDAMB231 cells overexpressing miR-148b compared to controls. Conversely, down-modulation of miR-148b in MCF7 and T47D cells led to decreased adhesion (Supplemental Fig. S2C) .
To study the role of miR-148b in in vivo metastasis formation, we injected miR-148b-overexpressing (premiR-148b) 4T1 cells into the tail vein of female BALB/c syngeneic mice, and analyzed dissemination in lungs. A significant reduction in the number of lung colonies or area occupied by the lesions was found 5 d postinjection compared with controls, as measured in hematoxylin and eosin (H&E)-stained sections ( Fig. 2A) . More relevantly, when red fluorescent pLemiR-148b-transduced, 4175TGL cells were injected orthotopically into NOD/SCID/IL2R␥ null mice and primary tumors formed, a striking reduction of malignant cell dissemination from the primary tumors to the lungs was observed com- pared to controls (Fig. 2B) . Quantitations refer to the red fluorescent metastatic foci (number/area) in the lungs at 12 d postinjection (Fig. 2B) ; H&E sections are shown (Fig. 2B) . Similar results were obtained with pLemiR-148b-transduced 4T1 cells (not shown). Notably, when similar experiments were previously performed with miR-214-overexpressing 4T1 cells, increased dissemination was observed (12) .
Based on this, we assessed the involvement of miR148b in extravasation and survival in the blood circulation, two essential steps of the metastatic dissemination.
To investigate extravasation in vivo, red fluorescent pLemiR-148b-transduced MDAMB231 cells were injected into the tail vein of immunocompromised mice, and cell seeding and extravasation in the lung were evaluated at 2 or 48 h postinjection. A high percentage of cells lodged in the lung at 2 h (within the vessels or outside) in the presence or absence of miR-148b. However, extravasation was highly reduced for miR148b-overexpressing cells compared to controls, as quantitation of the area occupied by metastatic cells showed (Fig. 2C, D) . Vessels were labeled for CD31 ( Fig. 2C) . To investigate survival in the blood circulation, we evaluated apoptosis in miR-148b-overexpressing MDAMB231 cells kept without serum and with or without (anoikis) adhesion for 48 h by cytofluorimetric analyses, and reduced survival was observed compared to controls (Fig. 2E ), which suggests a potential role for miR-148b in tumor cell intraluminal viability and initial survival. All these experiments strongly suggest that miR-148b is involved in metastatic cell dissemination by controlling tumor growth and cell survival in anoikis but mostly by inhibiting cell escaping through the endothelial cells of the vessels.
miR-148b expression enhances chemotherapy-induced apoptosis
Considering the relevance of chemotherapy response for tumor progression, we analyzed the response to paclitaxel, doxorubicin, and cisplatin following 24 or 48 h treatment in miR-148b-overexpressing (MDAMB231, 4175TGL, 4T1) or down-modulated (T47D) cells by cytofluorimetric analyses. A significant modulation in cell survival was found for all cell lines and treatments compared to controls (Fig. 3) , favoring a positive role for miR-148b in chemotherapy response.
miR-148b modulates multiple genes
To identify genes directly or indirectly modulated by miR-148b, miR-148b-overexpressing MDAMB231 cells were first used to perform whole human genome gene expression analysis. A total of 129 differentially expressed genes (49 up-regulated; 80 down-regulated) were found, considering a 1.5-fold change and a 16% FDR (Supplemental Table S1 ). qRT-PCR analysis was used to validate expression of the nonmodulated NRAS, ROCK1, PI3KCA, COPZ1, GRB2, and CXCL5 and of the differentially expressed DYRK2, CSF1, CTSA, ITGA5, MMP15, and NRP1 (not shown). By crossing these results with putative miR-148b targets (TargetScan 5.1), 20 common genes (19 down-regulated; 1 up-regulated) were found (Fig. 4A) , among them ITGA5, known to modulate apoptosis, adhesion, migration, and invasion (29, 30) , and CSF1, involved in tumor-stroma interactions (31, 32) . Using TargetScan predictions for an IPA, GM-CSF and integrin pathways were identified as statistically significant (Supplemental Fig. S3 ). Therefore, we investigated the plausible direct regulation of these pathways by miR-148b and their involvement in breast tumor progression. Protein expression was evaluated for ITGA5 and its downstream players ROCK1, PI3KCA/p110␣, and NRAS (predicted targets) and for CSF1 in miR-148b-overexpressing MDAMB231 or 4175TGL cells by Western blot analysis. Strong reductions were found compared to controls (Fig. 4B) . Instead, when miR-148b was down-modulated in MCF7 cells, increased levels of ITGA5 proteins were observed (Fig. 4B) . Interestingly, ROCK1, PI3KCA/ p110␣, and NRAS were not modulated at the mRNA level (not shown). Direct modulation of miR-148b on its targets was proven by performing luciferase assays in miR-148b-overexpressing or control MDAMB231 cells transfected with reporter vectors containing wild-type or mutated 3=-UTRs (Fig. 4C, D) . As positive control, a miR-148b-sensor construct was used (Fig. 4C) . Notably, when we evaluated miR-148b target expression on a subset of relapsing/nonrelapsing human tumors, differential expression was found (Fig. 5A) . Relevantly, when the 23 predicted and modulated miR-148b target genes were used in IPA to look for gene connections, cell-to-cell signaling and interaction, tissue development, cellular movement network was identified (Ingenuity scoreϭ22; Fig. 5B ). Given the relevance of the integrin pathway in our investigations, we evaluated the possibility that the upstream player ITGA5 can be used to predict survival in a large microarray dataset of human breast tumors (26) . Performing hierarchical clustering and Kaplan-Meier analyses and referring to ITGA5 median expression, we predicted DFS (Fig. 5C ). This, together with similar results reported previously (33) , suggests that repression of ITGA5 correlates with better clinical outcome and can be used as a prognostic marker.
Down-modulation of ITGA5 accounts for miR-148b chemotherapy response
The effect of integrin signaling on cell survival and chemotherapy response was evaluated in the absence of serum and adhesion (anoikis) or in presence of paclitaxel. When ITGA5 was silenced with siRNAs in MDAMB231 cells, reduction in cell survival was observed in anoikis conditions and for paclitaxel-treated cells vs. controls (Fig. 6A) . Instead, when ITGA5 (cDNA lacking its 3=-UTR) was overexpressed (pEGFP-ITGA5), together with pre-miR-148b, in MDAMB231 or MCF7 cells (Fig. 6B) , and with cells kept in the presence of paclitaxel, the effect of miR-148b on cell death was abolished (Fig. 3) . Figure 6B considers only the difference (⌬) observed when comparing the presence or absence of miR-148b. ITGA5 and miR-148b levels were evaluated by qRT-PCR analysis (Fig. 6C-E) . From these results, we can conclude that ITGA5 directly controls, at least partially, miR-148b-driven apoptosis in anoikis conditions and in the presence of paclitaxel.
DISCUSSION
In this work, we identified a group of 16 miRs that are associated with bad prognosis in our breast cancer patient cohort, and we revealed the function of miR-148b as a metastasis suppressor in mice, as well as its molecular mechanism of action. The identification of a group of miRs that could identify primary tumor subtypes is highly relevant for the clinics. In fact, it represents a potent molecular tool that clinicians can use at the time of surgery to attempt the most appropriate therapy for every patient. The strength of this tool is further marked by the fact that single components of the signature, for instance miR-148b, can predict tumor outcome individually. Relevantly, low levels of miR-148b were observed previously in basal-like (9) and ERBB2 ϩ /ER Ϫ /PR Ϫ (34) breast tumors, which suggests its involvement in malignancy.
Our functional experiments with metastatic cells strongly suggest that miR-148b exerts its metastasissuppressing role mostly by controlling cell movement. In fact, while it is true that ectopic expression of miR-148b in malignant tumor cells leads to decreased tumor growth, this effect is modest and not sufficient to justify the much more pronounced control of metastasis dissemination. On this line, increased miR-148b levels lead to stronger adhesion and anoikis and reduce invasion in vitro. Moreover, in vivo, miR-148b strongly reduces extravasation and lung colonization shortly after injection of the cells in the blood circulation, when proliferation has no time to play a major role. Overall, it is well accepted that miRs have pleiotropic functions and therefore can act in independent events, such as tumor formation and progression, via the activation/repression of a selective and rate-limiting cascade of specific genes (8, 35-37). (Fig. 4A) plus the 3 direct targets, ROCK1, PIK3CA, and NRAS, were used to perform an IPA searching for gene connections; the cell-to-cell signaling and interaction, tissue development, cellular movement functional network was generated. Ingenuity score: Ϫlog 10 P ϭ 22. Gene products are represented as nodes and biological relationships between two nodes as a line. Continuous lines indicate direct interactions; dashed lines represent indirect connections. Shapes of nodes symbolize functional classes of gene products (see legend in panel). Gray symbols indicate down-regulation; white symbols indicate genes absent in the input but related with the dataset used. C) Kaplan-Meier analyses of the probability of DFS of breast cancer patients based on ITGA5 expression (median) in Wang et al. (26) dataset for 286 breast tumor samples. P value was calculated using the log-rank test.
Among all the miR-148b-modulated genes identified in this study, many are known to be relevant in tumor progression, among them, CTSA, NRP1, CSF1, MMP15, and ITGA5, all suppressed by miR-148b. By focusing on the ITGA5 signaling, we found that not only ITGA5 but also ROCK1, PIK3CA/p110␣, and NRAS are directly down-regulated by miR-148b, which suggests a specific control for this miR on a pathway known to be involved in metastasis dissemination and chemotherapy response. In fact, ITGA5 and ROCK1 were found previously to be highly expressed in malignant breast tumors and are known to increase tumor growth or progression (33, 38 -42) . At the same time, PIK3CA/p110␣ is relevant for mammary tumorigenesis and angiogenesis (43) , as well as for resistance to endocrine or anti-HER2 therapies (44, 45) . In addition, NRAS is a well-known oncogene, and its silencing in tumor cells leads to increased apoptosis (46) . Regarding chemotherapy response, elevated levels and activity of ␣5␤1 have previously been implicated in drug resistance (47) , and inhibition of ␣5␤1/fibronectin interactions promotes apoptosis in malignant cells and enhances radiation effects (33) . In addition, perturbations of the actin cytoskeleton integrity via ROCK1 inhibition commit cells to apoptosis (48) . Remarkably, ITGA5 and its downstream player RHOA, a ROCK activator, have been previously found to be suppressed by miR-31, another small noncoding RNA that suppresses metastasis (36) . In addition, ROCK1 and RHOC are also directly targeted by two other miRs involved in tumor progression, miR-146a/b and miR-10b (49, 50) . The fact that CSF1 is also a direct target of miR-148b opens up a role for this small RNA in tumor-stroma cell interactions, which will be part of a future study. In summary, our study unravels the association of a group of 16 miRs with bad prognosis tumors and identifies miR-148b as a suppressor of tumor progression and modulator of chemotherapy response acting via the integrin. Low AnnexinV, healthy cells; High AnnexinV, apoptotic cells. Two or 3 independent experiments were performed in duplicate; pooled quantitations are shown as means Ϯ sd. C-E) qRT-PCR analyses were performed to evaluate ITGA5 mRNA or miR-148b expression for the cells shown in A and B. Two independent experiments were performed in triplicate, and a representative one is shown. ns, not significant. *P Ͻ 0.05; **P Ͻ 0.01.
